Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial

Antoine Roquilly; Bruno François; Olivier Huet; Yoann Launey; Sigismond Lasocki; Emmanuel Weiss; Mélanie Petrier; Yannick Hourmant; Marwan Bouras; Karim Lakhal; C. Bel; Delphine Flattres Duchaussoy; Laia Fernández‐Barat; Adrián Ceccato; Laurent Flet; Alexandra Jobert; Jérémie Poschmann; Véronique Sebille; Fanny Feuillet; Despoina Koulenti; Antoní Torres; Nicolas Grillot; Karim Asehnoune; Alexandre Bourdiol; Dominique Demeure Dit Latte; A Armaganidis; Nicolas Nesseler; Philippe Séguin

doi:10.1007/s00134-023-07065-0

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Among mechanically ventilated patients with acute organ failure, treatment with interferon gamma-1b compared with placebo did not significantly reduce the incidence of hospital-acquired pneumonia or death on day 28. Furthermore, the trial was discontinued early due to safety concerns about interferon gamma-1b treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roquilly et al. (2023) studied this question.

synapsesocial.com/papers/69dff1a71827a1d0b1255516 https://doi.org/10.1007/s00134-023-07065-0

View Full Paper

Ask AI

Bookmark

Share

Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial

Ask about this paper

Abstract

Discussion

Cite This Study

Interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a phase 2, placebo-controlled randomized clinical trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading